This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Sep 2021

SK Capital Partners in discussions to create an integrated global API CDMO leader

The private investment firm plans to acquire SEQENS and merge it with Wavelength Pharmaceuticals

SK Capital Partners has entered into exclusive discussions to acquire a majority stake in SEQENS — an integrated developer and manufacturer of active pharmaceutical ingredients (APIs), advanced drug intermediates and specialty ingredients.

The company also plans to merge one of its portfolio companies, Wavelength Pharmaceuticals, to create a global leader in the API & CDMO sectors.

Both elements of the deal are expected to complete by the end of 2021.

SEQENS is headquartered in France, and through its 3000 employees in 19 production sites and seven R&D centers around the world, generates an annual turnover of over €1 billion.

The company focuses on critical consumer care analgesic APIs, offering a broad portfolio of generic APIs and intermediates, as well as custom development and manufacturing services across a wide range of pharmaceutical technologies.

Wavelength Pharmaceuticals, a developer and manufacturer of APIs, produces more than 630 metric tons of commercial products every year and offers a full range of API CDMO services from preclinical grams to multi-ton commercial scale.

The proposed merger will create a scaled leader of global industrial footprint and further extend both companies’ broad portfolio of products, services and advanced pharmaceutical technologies; it could also increase the group’s industrial footprint, its product and technology portfolio.

Mentioned Companies
View company profile
Wavelength Pharmaceuticals
View company profile

Related News